This pilot QI project results indicate that many patients were not aware of the difference between the vaccines they received or when they received; this made successful vaccination difficult.
Efficacy of Influenza and Pneumococcal Vaccination in Preventing COPD
Background. Common causes of exacerbations in chronic obstructive airway disease (COPD) are due to infections by respiratory viruses and bacteria. Influenza vaccine and pneumococcal vaccine have demonstrated decrease in infective exacerbations in this population.
Methods. In this prospective study over 2 years, 146 COPD patients confirmed by spirometry in accordance with GOLD criteria and who received both influenza and pneumococcal polysaccharide vaccine were compared with 146 unvaccinated controls. Number of acute exacerbations, hospitalizations, ICU admissions, need for invasive mechanical ventilation, mortality difference for 1 year following vaccination were compared.
Results. In vaccinated group there was statistically significant reduction in number of exacerbations of COPD, requirement of hospitalization, ICU admissions and mortality which is depicted in the table. Requirement of mechanical ventilation was higher among cases compared with controls more so among GOLD 3 and 4, which is statistically significant. Subgroup analysis showed a significantly less hospitalization, ICU admission and mortality among vaccinated belonging to GOLD 1 and GOLD 2 as compared with matched controls. Also more exacerbations, hospitalizations, ICU admissions and mortality were observed in GOLD 3 and GOLD 4 who were not vaccinated. But this difference was not statistically significant.
Conclusion.
Overall there was significantly lesser number of exacerbations, hospitalizations, ICU admissions, requirement of mechanical ventilation and mortality among vaccinated group as compared with controls. Subgroup analysis showed a significant benefit from vaccination in COPD GOLD 1 and 2.
Disclosures. Background. PLZ is a next-generation aminoglycoside with potent in vitro activity against multidrug-and carbapenem-resistant EB. The objective of this study was to assess the efficacy of PLZ human-simulated exposure, alone and in combination with MEM or TGC, against EB in the I+ murine septicemia model.
Methods. ICR mice were inoculated intraperitoneally with bacterial suspensions of 10 6.5 CFU/mL. Eight EB isolates with PLZ, MEM and TGC MICs ranging from 2 to 16, ≤0.015 to >32, and ≤0.06 to 2 mg/L, respectively, were utilized to assess the efficacy of PLZ alone or in combination against isolates at the upper end of PLZ MIC distribution. PLZ, MEM and TGC doses in mice that mimic the human plasma exposures following the administration of the clinical doses summarized in the table were utilized.
Drug
Human Dose PLZ 15 mg/kg Q24H, 0.5 h infusion MEM 2 g Q8H, 3 hours infusion TGC 50 mg Q12H Treatment mice were administered PLZ, MEM or TGC human-equivalent doses alone or in combinations of PLZ/MEM and PLZ/TGC, while control mice were administered vehicle. Treatments were initiated 1 hours post-infection and continued for 24 hours. Efficacy was assessed by survival through 96 hours. Survival was compared using Kaplan-Meier analysis and log-rank test.
Results. Compared with controls, human-simulated exposure of PLZ monotherapy produced significant improvement in survival for all isolates (P < 0.05) and resulted in overall survival percentages of 86 (n = 50) and 53.3 (n = 30) for isolates with MIC ≤4 and ≥8 mg/L, respectively (P < 0.05). Survival of MEM and TGC groups correlated well with their respective susceptibilities, with incremental increase in survival observed at lower MIC values. For isolate KP 561 (PLZ, MEM and TGC MICs of 8, >32 and 2 mg/L, respectively), PLZ/MEM and PLZ/TGC showed significant reduction in mortality compared with any of the single agents (P < 0.05) (Fig 1) .
Conclusion. PLZ monotherapy resulted in improved survival in the I+ murine septicemia model, notably for isolates with MIC ≤4. Moreover, some evidence suggests that co-administration of MEM or TGC could potentially lead to further improvement in survival. These preclinical data utilizing clinically relevant exposures support a role for PLZ in the management of septicemia due to EB, including carbapenem-resistant isolates. 
